Impact of stratifin/14-3-3σ on survival and interstitial lung disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04093-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Daiki Murata und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, F…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms, Lung Diseases, Interstitial. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
BACKGROUND: Stratifin/14-3-3σ (SFN) is a new diagnostic biomarker of interstitial lung disease (ILD) with a diffuse alveolar damage (DAD) pattern as well as a predictor of resistance to anticancer therapy. Despite the potential clinical benefit of SFN, its impact on therapeutic efficacy of immune checkpoint inhibitors (ICIs) and ICI-induced interstitial lung disease (ICI-ILD) in patients with non-small cell lung cancer (NSCLC) receiving cancer immunotherapy is unknown. METHODS: Plasma samples were collected from patients with NSCLC at ICI initiation and 6 weeks later. The relationship between SFN levels and therapeutic efficacy of ICIs and development of ICI-ILD was analyzed. RESULTS: Pre-SFN levels were measured for 165 patients and post- and delta-SFN levels were measured for 113 patients. Of the patients with pre-SFN values, 25 developed ICI-ILD and 10 exhibited a DAD pattern. Among patients with post- and delta-SFN values, 15 developed ICI-ILD, and 6 had a DAD pattern. Pre- and post-SFN levels were not associated with ICI therapeutic efficacy or ICI-ILD. Meanwhile, delta-SFN, representing the change in SFN values between ICI initiation and at the 6-week point, was associated with progression-free survival, overall survival, disease control rate, and ICI-ILD image patterns. CONCLUSION: SFN levels in plasma were associated with therapeutic efficacy and ICI-ILD pattern in patients with NSCLC receiving cancer immunotherapy. SFN can be a diagnostic biomarker for ICI-ILD with DAD patterns as well as a prognostic biomarker for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, Japan.
- Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka, Japan. azuma@med.kurume-u.ac.jp.
- Biostatistics Center, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Murata, D., Azuma, K., Murotani, K., Zaizen, Y., & Hoshino, T. (2025). Impact of stratifin/14-3-3σ on survival and interstitial lung disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04093-1
Vancouver
Murata D, Azuma K, Murotani K, Zaizen Y, Hoshino T. Impact of stratifin/14-3-3σ on survival and interstitial lung disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04093-1
BibTeX
@article{Murata2025,
author = {Murata, Daiki and Azuma, Koichi and Murotani, Kenta and Zaizen, Yoshiaki and Hoshino, Tomoaki},
title = {Impact of stratifin/14-3-3σ on survival and interstitial lung disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04093-1}
}
EUVIMED